title: CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
abstract: OBJECTIVE
  To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP).
  
  
  METHODS
  Data were from patients enrolled in a 52-week randomized, double-blind, placebo-controlled study of DAC HYP and its extension study. Assessments included relationships of CD56(bright) NK cell numbers (identified using fluorescence-activated cell sorting) at weeks 4 and 8 with the numbers of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 and the annualized relapse rate.
  
  
  RESULTS
  In DAC HYP-treated patients but not placebo-treated patients, the numbers of CD56(bright) NK cells increased over 52 weeks of treatment, and their numbers at weeks 4 and 8 predicted the number of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 of treatment (p ≤ 0.005 for each comparison). Similar but nonsignificant trends were observed between CD56(bright) NK cell counts and the annualized relapse rate in DAC HYP-treated patients. DAC HYP-treated patients who showed lower levels of expansion of CD56(bright) NK cells still developed fewer new or newly enlarging T2-hyperintense lesions than placebo-treated patients during the first year of treatment.
  
  
  CONCLUSIONS
  CD56(bright) NK cells appear to mediate some of the treatment-related effects of DAC HYP, but their numbers do not account for the full effect of DAC HYP on MS-related outcomes.
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: J
authors: J
authors: Elkins
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: J
authors: J
authors: Sheridan
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: L
authors: L
authors: Amaravadi
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: K
authors: K
authors: Riester
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: K
authors: K
authors: Selmaj
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: B
authors: B
authors: Bielekova
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: E
authors: E
authors: Parr
authors: Biogen Idec (J.E., L.A., K.R.), Cambridge, MA; AbbVie Biotherapeutics Inc. (J.S.), Redwood City, CA; Medical University of Lodz (K.S.), Poland; Neuroimmunology Branch (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Excel Scientific Solutions (E.P.), Southport, CT; and Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
authors: G
authors: G
authors: Giovannoni
references: Neurology. 1988 Nov;38(11):1739-44
references: 3185908
references: J Exp Med. 1997 Nov 17;186(10):1677-87
references: 9362528
references: J Clin Immunol. 2002 Mar;22(2):51-6
references: 11998892
references: Mult Scler. 2011 Dec;17(12):1441-8
references: 21807759
references: J Immunol. 2011 Jul 15;187(2):781-90
references: 21666061
references: Lancet. 2013 Jun 22;381(9884):2167-75
references: 23562009
references: J Immunol. 2010 Jul 15;185(2):1311-20
references: 20543101
references: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
references: 16585503
references: Lancet Neurol. 2014 May;13(5):472-81
references: 24656609
references: Ann Neurol. 2011 Apr;69(4):721-34
references: 21425186
references: Clin Exp Immunol. 1982 Feb;47(2):419-30
references: 6176377
references: Clin Exp Immunol. 1980 Mar;39(3):657-62
references: 6155232
references: Lancet Neurol. 2010 Apr;9(4):381-90
references: 20163990
references: Sci Transl Med. 2012 Aug 1;4(145):145ra106
references: 22855463
references: J Neuroimmunol. 2005 Jun;163(1-2):24-30
references: 15885305
references: Nat Med. 2011 May;17(5):604-9
references: 21532597
references: Clin Exp Immunol. 1982 Jul;49(1):11-21
references: 6181920